Open AccessHouse dust mite SLIT-tablet is well tolerated in pediatric patients with controlled asthma
Author(s) -
Hisashi Tanida,
Takayasu Nomura,
Yuto Kondo,
Yu Hirabayashi,
Jun Wakatsuki,
Shinji Saitoh
Publication year - 2021
Publication title -
asian pacific journal of allergy and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.405
H-Index - 33
ISSN - 0125-877X
DOI - 10.12932/ap-051220-1009
Subject(s) - medicine , slit , asthma , house dust mite , sublingual immunotherapy , cohort , adverse effect , allergy , pediatrics , allergic asthma , pyroglyphidae , allergen , immunology , genetics , biology
: Despite the reported clinical effectiveness of house dust mite (HDM) sublingual immunotherapy (SLIT) in pediatric patients, the risk of treatment remains unclear in pediatric patients with allergic asthma.